US FDA warns public of fraudulent stem cell schemes
This article was originally published in Scrip
Executive Summary
US regulators warned consumers about fraudsters peddling potentially dangerous and ineffective stem cell treatments, noting that only one stem cell product is approved by the US FDA – Hemacord, a hematopoietic progenitor cell product derived from cord blood, which is manufactured by the New York Blood Center and used for specified indications in patients with disorders affecting the body’s blood-forming system.